The development of new cancer drugs is a complex, multi-phase process. Pharmacologists start with the identification of potential drug targets, such as specific proteins or genetic mutations associated with cancer. They then engage in drug discovery, utilizing various techniques to create compounds that can interact with these targets. This is followed by preclinical studies, where the efficacy and safety of these compounds are tested in cell cultures and animal models before moving on to clinical trials.
